From Biopharmcatalyst.com ... | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

IDRA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1533 of 1552  at  10/3/2019 6:33:17 AM  by

auh2oman


From Biopharmcatalyst.com ...

 
 
$2.68
+0.01 +0.37%
28.8 million
$77.3 million
10/02/2019
Tap to view 7 drugs
Drug Indication Stage News
Tilsotolimod + ipilimumab - ILLUMINATE 204 Cancer - melanoma Phase 2 Phase 2 final data due
 
Tilsotolimod - ILLUMINATE 101 Solid tumors Phase 1 Phase 1b data at AACR April 2019 noted 45% disease control rate.
Tilsotolimod (IMO-2125) + ipilimumab - ILLUMINATE 301 Melanoma Phase 3 Phase 3 completion of enrolment due 1H 2020.
Tilsotolimod + nivolumab and ipilimumab - ILLUMINATE 206 Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase 2
 
 
 
 
 
 
 
 
 
 
 https://www.biopharmcatalyst.com/biotech-stocks/company-pipeline-database


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 125
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...